2012年第15卷05期
共19篇1. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. 987-96页
作者:Parthiv J,Mahadevia; Anthony S,Masaquel; Mark J,Polak; Leonard B,Weiner
2. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. 977-86页
作者:J,Smith-Palmer; C,Fajardo-Montañana; R F,Pollock; A,Ericsson; W J,Valentine
3. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. 956-76页
作者:Robert,Deuson; Mark,Danese; Susan D,Mathias; Marieke,Schoonen; Jon,Fryzek
4. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. 997-1018页
作者:Leonard B,Weiner; Anthony S,Masaquel; Mark J,Polak; Parthiv J,Mahadevia
5. Derivation of severity index for rheumatoid arthritis and its association with healthcare outcomes. 918-24页
作者:O,Baser; J,Du; L,Xie; H,Wang; A H,Dysinger; L,Wang
6. Burden of illness in idiopathic pulmonary fibrosis. 829-35页
作者:Harold R,Collard; Alex J,Ward; Stephan,Lanes; D,Cortney Hayflinger; Daniel M,Rosenberg; Elke,Hunsche
7. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. 887-96页
作者:Antoine C,El Khoury; Carolyn,Wallace; William K,Klimack; Homie,Razavi
8. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. 844-61页
作者:Angelika,Mehnert; Deborah,Nicholl; Hanna,Pudas; Monique,Martin; Alistair,McGuire
9. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. 836-43页
作者:Maneesha,Mehra; Ying,Wu; Ravinder,Dhawan
10. Healthcare-related characteristics of low vs normal folate levels among women of child-bearing age. 807-16页
作者:Vijay N,Joish; Grace,Lin; Richard,Lynen
11. The impact of non-severe hypoglycemic events on daytime function and diabetes management among adults with type 1 and type 2 diabetes. 869-77页
作者:Meryl,Brod; Torsten,Christensen; Donald M,Bushnell
12. Resource utilization and cost of heart failure associated with reduced ejection fraction in Swedish patients. 938-46页
作者:Jan,Stålhammar; Lee,Stern; Ragnar,Linder; Steven,Sherman; Rohan,Parikh; Rinat,Ariely; Gerhard,Wikström
13. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. 947-55页
作者:Ronda,Copher; Annamaria,Cerulli; Angela,Watkins; Maria,Laura Monsalvo
14. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. 897-905页
作者:J D,Belsey
15. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. 906-17页
作者:K Y,Westerhout; B G,Verheggen; C H,Schreder; M,Augustin
16. The economic impact of galantamine vs placebo: an analysis based on functional capacity in a Swedish cohort study. 1019-24页
作者:Anders,Wimo; Maren,Gaudig; Barbara,Schäuble; Erik,Jedenius
17. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. 817-28页
作者:Heather,McDonald; Alex,Diamantopoulos; Philip,Wells; Michael,Lees; Kerstin,Folkerts; Fiona,Forster; Jaithri,Ananthapavan